Low doses of transdermal fentanyl in opioid-naive patients with cancer pain

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2765-2768

  Mercadante, Sebastiano ^a,b   Porzio, Gianpiero ^c   Ferrera, Patrizia ^a   Aielli, Federica ^c   Adile, Claudio ^a   Ficorella, Corrado ^d  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c L'Aquila per la Vita Home Care Unit   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cancer pain; Opioids; Trandermal fentanyl

Indexed keywords

FENTANYL; OPIATE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; PAIN ASSESSMENT; QUALITY OF LIFE; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

AGED; ANALGESIA; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS; PAIN; PALLIATIVE CARE; TRANSDERMAL PATCH;

EID: 78349253374     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.532545     Document Type: Article

References (20)

1. World Health Organization. Cancer Pain Relief and Palliative Care. Geneva: WHO, 1990
2. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. JAMA 1995;274:1870-3
3. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain 2007;11:823-30
4. van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69
5. Vielvoye-Kerlmeer A, Mattern C, Uitendaal M. Transdermal fentanyl in opioid-naive cancer patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000;19:185-92
6. Tawkfik MO, Bryuzgin V, Kourteva G. Use of transdermal without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 2004;20:259-67
7. Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13:888-94
8. Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27:409-16
9. Koizumi W, Toma H, Watanabe K. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-na?̈ve cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol 2004; 34:608-14
10. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006;31:242-7
11. De Conno F, Ripamonti C, Fagnoni E, et al. MERITO Study Group. The MERITO study: a multicenter trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat Med 2008;22:214-21
12. Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal buprenorphine in opioid-naive cancer patients with pain. Clin Ther 2009; 25:1517-28
13. Addington-Hall JM, MacDonald LD, Anderson HR. Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care? Br J Cancer 1990;62:695-9
14. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008;12:1040-6
15. Mystakidou K. Pain management of cancer patients with transdermal fenta-nyl: a study of 1828 step I, II & III transfers. J Pain 2004;5:119-32
16. Mystakidou K, Befon S, Tsilika E, et al. Use of fentanyl TTS as a single opioid for cancer pain relief: a safety and efficacy trial in patients naive to mild of strong opioids. Oncology 2002;62:9-16
17. Mystakidou K, Tsilika E, Kouloulias V. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer 2003;107:486-92
18. Mystakidou K, Befon S, Kouskouni E, et al. From codeine to transdermal for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001; 21:2225-30
19. Janssen, LP. Important drug warning. Available at: http://www.fda.gov/ medwatch/SAFETY/2005/duragesic-ddl-pdf
20. Otis J, Rothman M. A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin 2006;22:1493-501